Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Father and son spending Christmas together after health scares - 2A definitive Manual for 2024's Most In vogue Wedding Dresses
- 3December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- 4As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- 5PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- World’s tallest bridge and biggest museum named ‘greatest places of 2026’
- The Most Notable Design Brands of the 21st Hundred years
- This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment
- Prehistoric wolf’s gut frozen in time reveals an ice age giant
- Understanding Preschool Projects: Cultivating Abilities and Advancement
- French high-speed train slams into truck, killing TGV driver
- Little Urban areas to Visit in Western Europe
